Cognition Therapeutics CEO Kenneth I. Moch to Present at the Stifel 2017 Healthcare Conference

Posted by & filed under News.

Pittsburgh, Nov. 08, 2017 – Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that President & CEO Kenneth I. Moch will present at the Stifel 2017 Healthcare Conference at 8:45 a.m. on November 15, 2017 at… Read more »

Cognition Therapeutics’ Alzheimer’s Disease Candidate CT1812 Meets Phase 1b/2a Study Objectives: Well Tolerated with Positive Influence on Biomarkers of Synapse Recovery

Posted by & filed under News.

PITTSBURGH, Nov. 4, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today the presentation of the results of a randomized, multi-dose, placebo-controlled Phase 1b/2a clinical study (COG0102) of CT1812 as a Late-Breaking Oral Communication and… Read more »

Cognition Therapeutics to Present Results of CT1812 Phase 1b/2a Clinical Study as Late Breakers at CTAD Meeting on November 2nd and 4th

Posted by & filed under News.

PITTSBURGH, Oct. 30, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the biomarker and clinical results from the recently completed Phase 1b/2a clinical study (COG0102) of CT1812 will be presented in a Late-Breaking Poster… Read more »

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Posted by & filed under News.

Pittsburgh, Oct. 24, 2017 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a composition of matter patent for CT1812, Cognition’s first-in-class, orally available… Read more »

Cognition Therapeutics Receives Fast Track Designation from U.S. FDA for First-in-Class Alzheimer’s Candidate, CT1812

Posted by & filed under News.

PITTSBURGH, October 16, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its investigational drug CT1812 for the treatment of patients… Read more »

Cognition Therapeutics CEO Kenneth I. Moch to Present at Ladenburg Thalmann 2017 Healthcare Conference

Posted by & filed under News.

PITTSBURGH, September 20, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will present at the Ladenburg Thalmann 2017 Healthcare Conference at 9:00 a.m. on September 26, 2017 at the… Read more »

Cognition Therapeutics CEO Kenneth I. Moch Hosting One-on-Ones at Mizuho Securities CNS Deep Management Day

Posted by & filed under News.

PITTSBURGH, September 7, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will participate in the Mizuho Biotechnology Conference: CNS Deep Management Day on September 19, 2017 at the… Read more »

Function of Cognition Therapeutics’ Neurological Drug Screening Platform Presented at American Chemical Society National Meeting

Posted by & filed under News.

PITTSBURGH, Aug. 23, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that an oral presentation had been made at the American Chemical Society National Meeting highlighting the company’s phenotypic neuronal assay that has been… Read more »

Cognition Therapeutics Elects Lazard Vice Chairman Stephen Sands to Board of Directors

Posted by & filed under News.

Pittsburgh, Aug. 02, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Stephen Sands has joined the Company’s Board of Directors. Mr. Sands, the Vice Chairman of Investment Banking and Chairman of the Global… Read more »

Cognition Therapeutics CEO Kenneth I. Moch to Present at Canaccord Genuity Annual Growth Conference

Posted by & filed under News.

PITTSBURGH, July 31, 2017 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will present a corporate and clinical update at the Canaccord Genuity Annual Growth Conference on August 10,… Read more »